TG Therapeutics, Inc. announced the appointment of Kenneth Hoberman to the Company's Board of Directors. Mr. Hoberman is currently the Chief Operating Officer of Stemline Therapeutics, Inc.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.63 USD | -1.54% | +0.24% | -1.93% |
01/05 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
01/05 | Transcript : TG Therapeutics, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.93% | 241.77Cr | |
+45.48% | 5.81TCr | |
-6.28% | 4.05TCr | |
+37.52% | 3.9TCr | |
+13.21% | 2.67TCr | |
-12.01% | 2.66TCr | |
-21.69% | 1.9TCr | |
+0.69% | 1.22TCr | |
+23.62% | 1.2TCr | |
+24.82% | 1.19TCr |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- TG Therapeutics, Inc. Appoints Kenneth Hoberman to Board of Directors